ADA Scientific Sessions 2025 Abstract

Tirzepatide in Type 1 Diabetes—Safety, Tolerability, and Clinical Outcomes—Real-World Experience from a Large UK Center

By Simon A. Berry, Eleanor H. McNally, Iona Goodman, Daisy Elliott, Ahmed Iqbal

Study in peopleInterventions

The paper

Simon A. Berry, Eleanor H. McNally, Iona Goodman, Daisy Elliott, Ahmed Iqbal

Sheffield

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, oral 305-OR

doi.org/10.2337/db25-305-or

Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity